Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

August 15, 2016

Conditions

HER2-positive Breast CancerStage II Breast CancerStage IIIA Breast Cancer

Interventions

DRUG

lapatinib ditosylate

Given PO

DRUG

paclitaxel

Given IV

BIOLOGICAL

trastuzumab

Given IV

PROCEDURE

therapeutic conventional surgery

Undergo lumpectomy or mastectomy

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (3)

M D Anderson Cancer Center, Houston

Keio University, Shinjuku-ku

Saint Luke's International Hospital, Chūōku

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT01688609 - Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer | Biotech Hunter | Biotech Hunter